Human immunodeficiency virus (HIV) and psychiatric disorders frequently occur together and may result in concurrent use of atypical antipsychotic (AAP) agents and highly active antiretroviral therapy (HAART). Both classes of agents have been shown to cause clinically important dyslipidemia and metabolic dysregulation in a population at high baseline cardiovascular risk. The combined effects of concurrent use of these drug classes on lipids and other metabolic indices remain undetermined. This retrospective cohort included HIV(+) or HIV(-) patients at the Dallas Veterans Affairs Medical Center who received either HAART or AAP agents. Subjects were separated into three groups: HAART+AAP, HAART alone, and a control group of HIV(-) patients taking AAP agents.
Last date updated on March, 2021